| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 241 | 2024 | 1052 | 42.990 |
Why?
|
| Myeloid Differentiation Factor 88 | 66 | 2024 | 571 | 12.750 |
Why?
|
| Receptors, CXCR4 | 37 | 2021 | 726 | 8.040 |
Why?
|
| Adenine | 54 | 2024 | 936 | 7.150 |
Why?
|
| Pyrazoles | 43 | 2024 | 1972 | 6.320 |
Why?
|
| Piperidines | 56 | 2024 | 1602 | 5.840 |
Why?
|
| Immunoglobulin M | 64 | 2023 | 1537 | 5.790 |
Why?
|
| Pyrimidines | 45 | 2024 | 2942 | 5.650 |
Why?
|
| Antineoplastic Agents | 55 | 2023 | 13695 | 2.660 |
Why?
|
| Protein Kinase Inhibitors | 29 | 2023 | 5535 | 2.620 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 36 | 2015 | 693 | 2.470 |
Why?
|
| Mutation | 55 | 2023 | 29786 | 2.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 38 | 2021 | 11524 | 2.260 |
Why?
|
| Lymphoma, B-Cell | 12 | 2023 | 931 | 2.050 |
Why?
|
| Antibodies, Monoclonal | 45 | 2021 | 9274 | 1.970 |
Why?
|
| Proto-Oncogene Proteins c-hck | 5 | 2022 | 46 | 1.770 |
Why?
|
| Blood Viscosity | 8 | 2019 | 124 | 1.620 |
Why?
|
| Bone Marrow | 22 | 2021 | 2948 | 1.600 |
Why?
|
| Boronic Acids | 21 | 2015 | 965 | 1.580 |
Why?
|
| B-Lymphocytes | 26 | 2022 | 4665 | 1.570 |
Why?
|
| Pyrazines | 23 | 2021 | 1230 | 1.570 |
Why?
|
| Neoplasm Proteins | 11 | 2021 | 3703 | 1.480 |
Why?
|
| Multiple Myeloma | 60 | 2021 | 5181 | 1.400 |
Why?
|
| Receptors, IgG | 6 | 2011 | 582 | 1.320 |
Why?
|
| Apoptosis | 34 | 2020 | 9727 | 1.160 |
Why?
|
| Antigens, CD20 | 11 | 2019 | 199 | 1.080 |
Why?
|
| Humans | 323 | 2024 | 744343 | 1.060 |
Why?
|
| Quinazolinones | 3 | 2016 | 221 | 1.060 |
Why?
|
| Protein-Tyrosine Kinases | 16 | 2017 | 2455 | 1.050 |
Why?
|
| Plasma Cells | 9 | 2022 | 591 | 1.000 |
Why?
|
| Signal Transduction | 40 | 2022 | 23403 | 1.000 |
Why?
|
| Purines | 4 | 2016 | 594 | 0.990 |
Why?
|
| Antibodies, Neoplasm | 6 | 2011 | 286 | 0.960 |
Why?
|
| Disease-Free Survival | 20 | 2019 | 6895 | 0.960 |
Why?
|
| Aged | 95 | 2024 | 163280 | 0.950 |
Why?
|
| Aged, 80 and over | 54 | 2021 | 57776 | 0.920 |
Why?
|
| Plasmapheresis | 6 | 2017 | 211 | 0.910 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2015 | 177 | 0.890 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2016 | 523 | 0.870 |
Why?
|
| Middle Aged | 101 | 2021 | 213383 | 0.870 |
Why?
|
| Paraproteinemias | 10 | 2017 | 246 | 0.850 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2021 | 5172 | 0.830 |
Why?
|
| Sulfonamides | 4 | 2024 | 1938 | 0.810 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2014 | 625 | 0.800 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2015 | 1381 | 0.790 |
Why?
|
| Vidarabine | 6 | 2015 | 345 | 0.770 |
Why?
|
| Lymphoma | 6 | 2022 | 1877 | 0.750 |
Why?
|
| Antigens, CD | 12 | 2011 | 4026 | 0.740 |
Why?
|
| Thalidomide | 11 | 2013 | 890 | 0.740 |
Why?
|
| Immunization, Passive | 7 | 2005 | 623 | 0.730 |
Why?
|
| Survival Rate | 18 | 2021 | 12788 | 0.720 |
Why?
|
| Mutation, Missense | 3 | 2019 | 2564 | 0.720 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2020 | 789 | 0.690 |
Why?
|
| Male | 112 | 2023 | 350118 | 0.680 |
Why?
|
| Dexamethasone | 17 | 2023 | 1951 | 0.670 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2019 | 2942 | 0.650 |
Why?
|
| Amino Acid Substitution | 7 | 2019 | 1791 | 0.630 |
Why?
|
| Neoplasms, Second Primary | 3 | 2015 | 1061 | 0.630 |
Why?
|
| Female | 105 | 2023 | 380194 | 0.630 |
Why?
|
| Tumor Cells, Cultured | 39 | 2021 | 6314 | 0.610 |
Why?
|
| Retinal Diseases | 3 | 2009 | 683 | 0.610 |
Why?
|
| Point Mutation | 3 | 2021 | 1623 | 0.570 |
Why?
|
| Treatment Outcome | 42 | 2020 | 63114 | 0.560 |
Why?
|
| Genomics | 8 | 2022 | 5720 | 0.560 |
Why?
|
| Sirolimus | 5 | 2015 | 1564 | 0.560 |
Why?
|
| Nucleosides | 4 | 2010 | 138 | 0.550 |
Why?
|
| SEER Program | 4 | 2017 | 1508 | 0.540 |
Why?
|
| Adult | 65 | 2022 | 214055 | 0.540 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 1378 | 0.540 |
Why?
|
| Cyclophosphamide | 9 | 2023 | 2242 | 0.520 |
Why?
|
| Molecular Targeted Therapy | 7 | 2020 | 2727 | 0.520 |
Why?
|
| Cell Proliferation | 15 | 2018 | 10481 | 0.510 |
Why?
|
| Lung Injury | 1 | 2020 | 436 | 0.510 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6538 | 0.510 |
Why?
|
| Immunoglobulin G | 6 | 2016 | 4560 | 0.480 |
Why?
|
| Alkylating Agents | 5 | 2017 | 139 | 0.480 |
Why?
|
| Bone Marrow Cells | 10 | 2011 | 2513 | 0.480 |
Why?
|
| von Willebrand Factor | 1 | 2018 | 669 | 0.470 |
Why?
|
| Drug Tolerance | 1 | 2015 | 376 | 0.470 |
Why?
|
| Apoptosis Regulatory Proteins | 6 | 2015 | 1157 | 0.460 |
Why?
|
| Warts | 1 | 2013 | 68 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.460 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 281 | 0.450 |
Why?
|
| Antigens, Neoplasm | 4 | 2011 | 1988 | 0.450 |
Why?
|
| Glycoproteins | 4 | 2011 | 2263 | 0.450 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 632 | 0.440 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2017 | 685 | 0.440 |
Why?
|
| Mice, SCID | 15 | 2021 | 2716 | 0.440 |
Why?
|
| Disease Progression | 20 | 2021 | 13284 | 0.440 |
Why?
|
| Prognosis | 25 | 2021 | 29063 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1434 | 0.430 |
Why?
|
| Paraproteins | 4 | 2020 | 39 | 0.430 |
Why?
|
| Hydroxamic Acids | 4 | 2013 | 494 | 0.430 |
Why?
|
| Frameshift Mutation | 1 | 2014 | 399 | 0.430 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 39050 | 0.430 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2002 | 4420 | 0.430 |
Why?
|
| Cell Survival | 20 | 2018 | 5882 | 0.430 |
Why?
|
| Survival Analysis | 14 | 2020 | 10252 | 0.420 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 3 | 2018 | 78 | 0.420 |
Why?
|
| Mast Cells | 4 | 2008 | 1544 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2015 | 4554 | 0.410 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 3597 | 0.400 |
Why?
|
| NF-kappa B | 13 | 2020 | 2499 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2018 | 2503 | 0.400 |
Why?
|
| Salvage Therapy | 7 | 2018 | 1275 | 0.390 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2011 | 56 | 0.390 |
Why?
|
| Nitrogen Mustard Compounds | 4 | 2015 | 45 | 0.380 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 2007 | 307 | 0.380 |
Why?
|
| Polymorphism, Genetic | 5 | 2011 | 4328 | 0.380 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2016 | 895 | 0.380 |
Why?
|
| Polymerase Chain Reaction | 6 | 2015 | 6171 | 0.370 |
Why?
|
| Anemia | 3 | 2011 | 1506 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2018 | 8428 | 0.360 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 547 | 0.360 |
Why?
|
| Immunologic Factors | 5 | 2014 | 1580 | 0.360 |
Why?
|
| Vincristine | 4 | 2021 | 1039 | 0.350 |
Why?
|
| Membrane Glycoproteins | 11 | 2016 | 3768 | 0.350 |
Why?
|
| Syndrome | 4 | 2018 | 3251 | 0.330 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2013 | 365 | 0.330 |
Why?
|
| Cell Line, Tumor | 22 | 2021 | 16689 | 0.330 |
Why?
|
| Tunicamycin | 1 | 2008 | 112 | 0.330 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 697 | 0.330 |
Why?
|
| Recurrence | 13 | 2015 | 8340 | 0.330 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 362 | 0.330 |
Why?
|
| Lymphocytes | 3 | 2013 | 2617 | 0.320 |
Why?
|
| Prospective Studies | 12 | 2023 | 53288 | 0.320 |
Why?
|
| Agammaglobulinemia | 1 | 2009 | 167 | 0.320 |
Why?
|
| Hypergammaglobulinemia | 1 | 2008 | 74 | 0.320 |
Why?
|
| Consensus | 8 | 2023 | 2959 | 0.320 |
Why?
|
| Boron Compounds | 2 | 2020 | 178 | 0.310 |
Why?
|
| Interleukin-6 | 15 | 2016 | 3200 | 0.310 |
Why?
|
| Gene Expression Profiling | 13 | 2018 | 9438 | 0.310 |
Why?
|
| Genes, Regulator | 1 | 2009 | 378 | 0.310 |
Why?
|
| Doxorubicin | 6 | 2021 | 2234 | 0.300 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 2 | 2018 | 86 | 0.300 |
Why?
|
| Stilbenes | 1 | 2008 | 156 | 0.290 |
Why?
|
| Flow Cytometry | 13 | 2013 | 5974 | 0.290 |
Why?
|
| Prednisone | 4 | 2021 | 1574 | 0.290 |
Why?
|
| Mucin-1 | 3 | 2001 | 543 | 0.290 |
Why?
|
| Immunoglobulin A | 3 | 2009 | 992 | 0.290 |
Why?
|
| Hepatitis C Antibodies | 1 | 2007 | 145 | 0.290 |
Why?
|
| Family Health | 1 | 2011 | 1282 | 0.280 |
Why?
|
| Gene Expression | 9 | 2019 | 7799 | 0.280 |
Why?
|
| CD40 Ligand | 4 | 2006 | 526 | 0.280 |
Why?
|
| Stress, Physiological | 2 | 2011 | 1403 | 0.280 |
Why?
|
| Enzyme Inhibitors | 7 | 2011 | 3798 | 0.280 |
Why?
|
| Gene Deletion | 2 | 2013 | 2751 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2020 | 380 | 0.270 |
Why?
|
| Glycine | 2 | 2020 | 671 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 5442 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 2109 | 0.270 |
Why?
|
| Enzyme Activation | 11 | 2022 | 3701 | 0.260 |
Why?
|
| Simvastatin | 1 | 2008 | 360 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2009 | 3523 | 0.250 |
Why?
|
| Immunophenotyping | 9 | 2019 | 1880 | 0.250 |
Why?
|
| Biomedical Research | 2 | 2018 | 3309 | 0.250 |
Why?
|
| Retinal Vessels | 2 | 2008 | 772 | 0.250 |
Why?
|
| Iron | 1 | 2013 | 1774 | 0.250 |
Why?
|
| Sp1 Transcription Factor | 2 | 2016 | 144 | 0.240 |
Why?
|
| Receptors, Antigen, B-Cell | 3 | 2016 | 548 | 0.240 |
Why?
|
| beta 2-Microglobulin | 4 | 2020 | 315 | 0.240 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1401 | 0.240 |
Why?
|
| Endoplasmic Reticulum | 2 | 2018 | 1144 | 0.240 |
Why?
|
| Protease Inhibitors | 2 | 2007 | 791 | 0.240 |
Why?
|
| Mastocytosis | 1 | 2006 | 160 | 0.230 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 4933 | 0.230 |
Why?
|
| MicroRNAs | 6 | 2018 | 3752 | 0.230 |
Why?
|
| Mice, Inbred NOD | 5 | 2021 | 1878 | 0.230 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 272 | 0.230 |
Why?
|
| Killer Cells, Natural | 4 | 2007 | 2133 | 0.230 |
Why?
|
| Receptors, IgE | 1 | 2005 | 389 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2016 | 7880 | 0.220 |
Why?
|
| Stem Cell Transplantation | 5 | 2017 | 1620 | 0.220 |
Why?
|
| Hematocrit | 3 | 2011 | 636 | 0.220 |
Why?
|
| Epigenomics | 2 | 2020 | 903 | 0.220 |
Why?
|
| Lipopolysaccharides | 5 | 1994 | 2216 | 0.220 |
Why?
|
| Transplantation, Heterologous | 7 | 2007 | 2382 | 0.220 |
Why?
|
| Leucine | 2 | 2016 | 561 | 0.220 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 7913 | 0.220 |
Why?
|
| DNA-Binding Proteins | 8 | 2014 | 9648 | 0.220 |
Why?
|
| Cladribine | 2 | 2015 | 34 | 0.220 |
Why?
|
| Proline | 2 | 2016 | 458 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2245 | 0.210 |
Why?
|
| Neprilysin | 1 | 2005 | 439 | 0.210 |
Why?
|
| Amyloidosis | 3 | 2004 | 795 | 0.210 |
Why?
|
| Hemoglobins | 5 | 2018 | 1534 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2008 | 1352 | 0.200 |
Why?
|
| Interferon-gamma | 6 | 2002 | 3206 | 0.200 |
Why?
|
| Cyanosis | 1 | 2021 | 83 | 0.200 |
Why?
|
| Immunotherapy | 7 | 2017 | 4445 | 0.200 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1994 | 236 | 0.200 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 3647 | 0.200 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2421 | 0.190 |
Why?
|
| Caspase 1 | 1 | 2022 | 224 | 0.190 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2021 | 173 | 0.190 |
Why?
|
| Antigens, CD19 | 3 | 2014 | 380 | 0.190 |
Why?
|
| Immunoblotting | 4 | 2012 | 1682 | 0.190 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1941 | 0.190 |
Why?
|
| Immunotherapy, Active | 1 | 2000 | 60 | 0.190 |
Why?
|
| Algorithms | 3 | 2017 | 13881 | 0.190 |
Why?
|
| Oligopeptides | 3 | 2015 | 1189 | 0.190 |
Why?
|
| Phenotype | 4 | 2016 | 16365 | 0.190 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 138 | 0.180 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 12354 | 0.180 |
Why?
|
| Transcription Factors | 7 | 2015 | 12208 | 0.180 |
Why?
|
| Transplantation, Autologous | 3 | 2022 | 2124 | 0.180 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 977 | 0.180 |
Why?
|
| Incidence | 8 | 2018 | 20947 | 0.180 |
Why?
|
| Cell Line | 5 | 2018 | 15997 | 0.180 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 142 | 0.180 |
Why?
|
| Retrospective Studies | 18 | 2023 | 77449 | 0.180 |
Why?
|
| Neoplasms | 5 | 2022 | 21683 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 627 | 0.180 |
Why?
|
| Acrylamides | 2 | 2018 | 255 | 0.170 |
Why?
|
| Genotype | 5 | 2017 | 12951 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2014 | 7729 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2012 | 4751 | 0.170 |
Why?
|
| Histone Deacetylases | 3 | 2020 | 728 | 0.170 |
Why?
|
| Transcriptional Activation | 3 | 2016 | 1783 | 0.170 |
Why?
|
| Hepacivirus | 1 | 2007 | 1379 | 0.170 |
Why?
|
| Drug Synergism | 6 | 2018 | 1792 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2022 | 2916 | 0.170 |
Why?
|
| Disease Management | 3 | 2020 | 2459 | 0.170 |
Why?
|
| Case-Control Studies | 7 | 2020 | 21746 | 0.170 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 4186 | 0.170 |
Why?
|
| Registries | 1 | 2014 | 8089 | 0.170 |
Why?
|
| Models, Biological | 2 | 2014 | 9583 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 2915 | 0.170 |
Why?
|
| Portraits as Topic | 1 | 2018 | 33 | 0.170 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 5 | 2002 | 197 | 0.160 |
Why?
|
| Blood Proteins | 2 | 2016 | 1124 | 0.160 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 12959 | 0.160 |
Why?
|
| Cytokines | 7 | 2018 | 7322 | 0.160 |
Why?
|
| Animals | 36 | 2022 | 168757 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 460 | 0.160 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 152 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2007 | 2902 | 0.160 |
Why?
|
| Neutropenia | 3 | 2009 | 895 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 8863 | 0.160 |
Why?
|
| p21-Activated Kinases | 1 | 2018 | 128 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 3 | 2012 | 277 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2023 | 2649 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 4803 | 0.150 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 54 | 0.150 |
Why?
|
| Benzamides | 2 | 2021 | 1379 | 0.150 |
Why?
|
| DNA Methylation | 5 | 2020 | 4286 | 0.150 |
Why?
|
| Ophthalmoscopy | 2 | 2009 | 176 | 0.150 |
Why?
|
| Cells, Cultured | 8 | 2013 | 19229 | 0.150 |
Why?
|
| Aminopyridines | 2 | 2018 | 542 | 0.150 |
Why?
|
| Patient Care | 1 | 2023 | 640 | 0.150 |
Why?
|
| Time Factors | 11 | 2021 | 40075 | 0.150 |
Why?
|
| Protein Multimerization | 3 | 2017 | 970 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 249 | 0.150 |
Why?
|
| Plasma | 1 | 2020 | 575 | 0.150 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2008 | 242 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2022 | 495 | 0.150 |
Why?
|
| Mice | 26 | 2022 | 81183 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2021 | 3474 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2019 | 297 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 1602 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 326 | 0.140 |
Why?
|
| Phosphorylation | 13 | 2016 | 8436 | 0.140 |
Why?
|
| Antimetabolites | 2 | 2014 | 125 | 0.140 |
Why?
|
| Glucuronosyltransferase | 2 | 2008 | 128 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2021 | 1850 | 0.140 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 127 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 2018 | 277 | 0.140 |
Why?
|
| Hematology | 1 | 2019 | 221 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2007 | 1591 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2019 | 17446 | 0.140 |
Why?
|
| Caspases | 4 | 2011 | 928 | 0.140 |
Why?
|
| Biopsy | 5 | 2019 | 6756 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 35421 | 0.140 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2018 | 233 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 9 | 2020 | 7279 | 0.140 |
Why?
|
| Chromosome Aberrations | 4 | 2014 | 1813 | 0.140 |
Why?
|
| Chemokine CXCL12 | 2 | 2015 | 464 | 0.130 |
Why?
|
| Glucocorticoids | 3 | 2003 | 2107 | 0.130 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2016 | 101 | 0.130 |
Why?
|
| Alleles | 3 | 2019 | 6933 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5686 | 0.130 |
Why?
|
| Cell Division | 10 | 2000 | 4568 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 6489 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2016 | 719 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 6773 | 0.130 |
Why?
|
| Cyclophilin A | 1 | 2015 | 57 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 18029 | 0.130 |
Why?
|
| Exanthema | 1 | 2019 | 501 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2016 | 528 | 0.130 |
Why?
|
| Autoantibodies | 2 | 2000 | 2035 | 0.130 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2014 | 7 | 0.130 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2014 | 32 | 0.120 |
Why?
|
| Herpesvirus 8, Human | 4 | 2000 | 258 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 180 | 0.120 |
Why?
|
| Piperazines | 1 | 2004 | 2488 | 0.120 |
Why?
|
| Mutant Proteins | 1 | 2016 | 500 | 0.120 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 491 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2017 | 2938 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 592 | 0.120 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2014 | 170 | 0.120 |
Why?
|
| Periodicals as Topic | 2 | 2018 | 1432 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 3557 | 0.120 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2013 | 73 | 0.110 |
Why?
|
| Protein Binding | 4 | 2017 | 9386 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 4 | 1999 | 494 | 0.110 |
Why?
|
| Oxazines | 1 | 2015 | 298 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2008 | 1423 | 0.110 |
Why?
|
| Reye Syndrome | 1 | 1992 | 28 | 0.110 |
Why?
|
| Translocation, Genetic | 2 | 2021 | 1420 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 10943 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 8642 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3255 | 0.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1832 | 0.110 |
Why?
|
| Medical Oncology | 2 | 2017 | 2265 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 720 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2004 | 1285 | 0.110 |
Why?
|
| Remission Induction | 3 | 2014 | 2386 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 3 | 2003 | 1000 | 0.110 |
Why?
|
| Kupffer Cells | 1 | 1993 | 142 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 640 | 0.110 |
Why?
|
| Cell Adhesion | 6 | 2015 | 3144 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.110 |
Why?
|
| Drug Resistance | 2 | 2019 | 1609 | 0.110 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1994 | 294 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2013 | 18111 | 0.110 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 496 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1655 | 0.110 |
Why?
|
| Immunoglobulins | 2 | 2017 | 881 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11124 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1992 | 39 | 0.100 |
Why?
|
| Electrophoresis, Capillary | 2 | 2009 | 64 | 0.100 |
Why?
|
| Transferrin | 1 | 2013 | 295 | 0.100 |
Why?
|
| Cell Cycle | 4 | 2015 | 2967 | 0.100 |
Why?
|
| Proteomics | 4 | 2017 | 3638 | 0.100 |
Why?
|
| Sjogren's Syndrome | 1 | 2013 | 233 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2015 | 435 | 0.100 |
Why?
|
| Stem Cells | 1 | 2005 | 3567 | 0.100 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2012 | 83 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.100 |
Why?
|
| Cell Communication | 2 | 2018 | 1621 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 2948 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2015 | 695 | 0.100 |
Why?
|
| Stomatitis | 1 | 2014 | 269 | 0.100 |
Why?
|
| Luciferases | 1 | 2013 | 733 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 2866 | 0.100 |
Why?
|
| Cell Movement | 6 | 2015 | 5217 | 0.100 |
Why?
|
| Base Sequence | 5 | 2016 | 12797 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 905 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 13102 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2009 | 1179 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1526 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 783 | 0.090 |
Why?
|
| Hepatitis | 1 | 1992 | 227 | 0.090 |
Why?
|
| Lentivirus | 1 | 2013 | 501 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 2011 | 403 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 987 | 0.090 |
Why?
|
| Nuclear Proteins | 5 | 2013 | 5853 | 0.090 |
Why?
|
| Ubiquitins | 1 | 2012 | 384 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 498 | 0.090 |
Why?
|
| Immunosuppressive Agents | 4 | 2012 | 4149 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 1017 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2011 | 647 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2022 | 2958 | 0.090 |
Why?
|
| Methotrexate | 1 | 1996 | 1727 | 0.090 |
Why?
|
| Stromal Cells | 4 | 2012 | 1355 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 15519 | 0.090 |
Why?
|
| Complementarity Determining Regions | 2 | 2007 | 149 | 0.090 |
Why?
|
| United States | 5 | 2021 | 69872 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2013 | 5179 | 0.080 |
Why?
|
| DNA Repair | 1 | 2018 | 2046 | 0.080 |
Why?
|
| Chlorambucil | 1 | 2008 | 43 | 0.080 |
Why?
|
| Asymptomatic Diseases | 3 | 2019 | 551 | 0.080 |
Why?
|
| Antigens, Nuclear | 2 | 2000 | 192 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 9734 | 0.080 |
Why?
|
| Coculture Techniques | 3 | 2012 | 1341 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 3870 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 9959 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 20822 | 0.080 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2009 | 104 | 0.080 |
Why?
|
| Transfection | 5 | 2011 | 5892 | 0.080 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 12072 | 0.080 |
Why?
|
| Neoplasm Transplantation | 5 | 2014 | 2085 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1788 | 0.080 |
Why?
|
| Down-Regulation | 6 | 2016 | 3002 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 5867 | 0.080 |
Why?
|
| TCF Transcription Factors | 1 | 2008 | 140 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 4462 | 0.080 |
Why?
|
| beta Catenin | 2 | 2015 | 1059 | 0.080 |
Why?
|
| Morbidity | 1 | 2013 | 1769 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 638 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2015 | 40561 | 0.070 |
Why?
|
| Genes, p16 | 2 | 1997 | 157 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2007 | 92 | 0.070 |
Why?
|
| Splenomegaly | 3 | 2003 | 190 | 0.070 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2007 | 57 | 0.070 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1708 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 271 | 0.070 |
Why?
|
| Diarrhea | 1 | 2014 | 1348 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2009 | 264 | 0.070 |
Why?
|
| Cell Differentiation | 4 | 2014 | 11483 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2018 | 3461 | 0.070 |
Why?
|
| Fatigue | 1 | 2014 | 1531 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2014 | 1915 | 0.070 |
Why?
|
| Platelet Count | 1 | 2009 | 781 | 0.070 |
Why?
|
| Trans-Activators | 3 | 2014 | 2924 | 0.070 |
Why?
|
| Catechin | 1 | 2006 | 66 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 3505 | 0.070 |
Why?
|
| Lymphatic Diseases | 3 | 2003 | 324 | 0.070 |
Why?
|
| Microtubules | 1 | 1992 | 1090 | 0.070 |
Why?
|
| Genes, Immunoglobulin | 2 | 2004 | 291 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2014 | 3494 | 0.070 |
Why?
|
| Interphase | 1 | 2005 | 226 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2022 | 775 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 2038 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 4740 | 0.060 |
Why?
|
| Caspase 9 | 2 | 2002 | 188 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2016 | 2149 | 0.060 |
Why?
|
| Viral Proteins | 3 | 2002 | 1900 | 0.060 |
Why?
|
| Protein Folding | 1 | 2008 | 843 | 0.060 |
Why?
|
| Caspase 8 | 2 | 2002 | 195 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
| Cancer Vaccines | 2 | 2004 | 1023 | 0.060 |
Why?
|
| Age Factors | 4 | 2018 | 18370 | 0.060 |
Why?
|
| Logistic Models | 1 | 2020 | 13408 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2022 | 4204 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2008 | 1375 | 0.060 |
Why?
|
| Retinoblastoma Protein | 2 | 1999 | 704 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 986 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1997 | 705 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 299 | 0.060 |
Why?
|
| VDJ Recombinases | 1 | 2004 | 84 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 11031 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 624 | 0.060 |
Why?
|
| Interleukin-17 | 1 | 2010 | 899 | 0.060 |
Why?
|
| DNA Helicases | 2 | 2000 | 859 | 0.060 |
Why?
|
| Receptors, Interleukin-6 | 3 | 2004 | 224 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 736 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 13815 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2014 | 2575 | 0.060 |
Why?
|
| Genetic Variation | 3 | 2016 | 6544 | 0.060 |
Why?
|
| Up-Regulation | 6 | 2007 | 4217 | 0.060 |
Why?
|
| Immunoglobulin delta-Chains | 1 | 2003 | 7 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2011 | 2715 | 0.060 |
Why?
|
| Karyotyping | 1 | 2005 | 1243 | 0.060 |
Why?
|
| Immunoglobulin J-Chains | 1 | 2003 | 27 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2016 | 758 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
| GPI-Linked Proteins | 1 | 2005 | 434 | 0.060 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 867 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 707 | 0.060 |
Why?
|
| Cell Death | 3 | 2016 | 1706 | 0.060 |
Why?
|
| Pyridines | 1 | 2015 | 2825 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2886 | 0.060 |
Why?
|
| Codon | 1 | 2005 | 611 | 0.060 |
Why?
|
| Risk Factors | 9 | 2019 | 72290 | 0.050 |
Why?
|
| Cryoglobulinemia | 1 | 2003 | 87 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 318 | 0.050 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2002 | 49 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2012 | 973 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 190 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 3920 | 0.050 |
Why?
|
| Sulfones | 1 | 2004 | 437 | 0.050 |
Why?
|
| Quality of Life | 2 | 2023 | 12804 | 0.050 |
Why?
|
| Neutralization Tests | 2 | 2001 | 758 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 4479 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2007 | 1227 | 0.050 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 176 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2002 | 115 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 2 | 2012 | 2728 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1366 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2016 | 440 | 0.050 |
Why?
|
| Macrophages | 2 | 1994 | 5655 | 0.050 |
Why?
|
| Splenectomy | 1 | 2003 | 395 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4037 | 0.050 |
Why?
|
| Sex Factors | 1 | 2015 | 10397 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 3772 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3086 | 0.050 |
Why?
|
| Cyclins | 3 | 1999 | 603 | 0.050 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 5034 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 215 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 11366 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2000 | 473 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 2 | 2006 | 2765 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2005 | 895 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 216 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 2004 | 2725 | 0.050 |
Why?
|
| Lectins | 1 | 2003 | 513 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2004 | 2015 | 0.050 |
Why?
|
| Recombinant Proteins | 5 | 2003 | 6622 | 0.050 |
Why?
|
| Liver | 2 | 1993 | 7474 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 659 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4776 | 0.050 |
Why?
|
| Immunomagnetic Separation | 1 | 2000 | 80 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
| G1 Phase | 2 | 2000 | 415 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 128 | 0.040 |
Why?
|
| Leukocytes | 1 | 2008 | 2043 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2000 | 252 | 0.040 |
Why?
|
| DNA Damage | 2 | 2018 | 2432 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2021 | 2618 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2022 | 551 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 2703 | 0.040 |
Why?
|
| Genome, Human | 1 | 2012 | 4420 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 694 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2010 | 162 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 686 | 0.040 |
Why?
|
| Propidium | 1 | 1998 | 41 | 0.040 |
Why?
|
| Kidney | 1 | 2014 | 7186 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 377 | 0.040 |
Why?
|
| Toremifene | 1 | 1998 | 24 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2005 | 5524 | 0.040 |
Why?
|
| Pain | 1 | 2014 | 4986 | 0.040 |
Why?
|
| Viral Core Proteins | 1 | 1999 | 162 | 0.040 |
Why?
|
| Clone Cells | 2 | 2016 | 1692 | 0.040 |
Why?
|
| Lymphokines | 1 | 2001 | 949 | 0.040 |
Why?
|
| Indoles | 1 | 2007 | 1839 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 74 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2018 | 189 | 0.040 |
Why?
|
| Retina | 1 | 2009 | 2616 | 0.040 |
Why?
|
| Massachusetts | 1 | 2011 | 8663 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1462 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2005 | 1904 | 0.040 |
Why?
|
| Leukemia, Plasma Cell | 1 | 1997 | 48 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2008 | 4199 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2016 | 769 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 217 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 692 | 0.040 |
Why?
|
| Phosphorylcholine | 2 | 2008 | 162 | 0.040 |
Why?
|
| Myeloma Proteins | 1 | 2017 | 72 | 0.040 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 7722 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2004 | 1348 | 0.040 |
Why?
|
| Graft Survival | 1 | 2007 | 3737 | 0.040 |
Why?
|
| Drug Discovery | 2 | 2016 | 1058 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1999 | 629 | 0.040 |
Why?
|
| Pneumonia | 1 | 2008 | 2133 | 0.040 |
Why?
|
| Plasmacytoma | 2 | 2011 | 183 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 56430 | 0.040 |
Why?
|
| World Health Organization | 1 | 2022 | 1318 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2000 | 233 | 0.040 |
Why?
|
| Autoantigens | 1 | 2000 | 892 | 0.030 |
Why?
|
| London | 1 | 2016 | 233 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5097 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3586 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2889 | 0.030 |
Why?
|
| Lung | 1 | 2014 | 9856 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1998 | 566 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3479 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2016 | 1547 | 0.030 |
Why?
|
| Integrin alpha4beta1 | 1 | 2015 | 121 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1997 | 315 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2002 | 2969 | 0.030 |
Why?
|
| Growth Substances | 1 | 1998 | 784 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1641 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2004 | 1369 | 0.030 |
Why?
|
| Bence Jones Protein | 2 | 2006 | 18 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2000 | 1678 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2003 | 2740 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2006 | 1596 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2017 | 374 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2004 | 489 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1357 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 563 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2010 | 1836 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1758 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 1996 | 231 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 684 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1997 | 671 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 1790 | 0.030 |
Why?
|
| Epitopes | 1 | 2000 | 2571 | 0.030 |
Why?
|
| Exosomes | 1 | 2018 | 417 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 2268 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 594 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1998 | 981 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 1085 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 474 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 2 | 2007 | 320 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 2274 | 0.030 |
Why?
|
| Reference Values | 1 | 2000 | 4982 | 0.030 |
Why?
|
| Electrophoresis | 1 | 2013 | 240 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 707 | 0.030 |
Why?
|
| Monokines | 1 | 1992 | 75 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2012 | 91 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 564 | 0.030 |
Why?
|
| Densitometry | 1 | 2012 | 156 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1415 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 157 | 0.030 |
Why?
|
| Salmonella | 1 | 1993 | 129 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2004 | 421 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2007 | 434 | 0.030 |
Why?
|
| Salivary Glands | 1 | 2013 | 229 | 0.030 |
Why?
|
| ras Proteins | 1 | 1997 | 1060 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 3616 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 6386 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 1999 | 452 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 513 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2000 | 1270 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 3271 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 571 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2007 | 3386 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 893 | 0.020 |
Why?
|
| Estradiol | 1 | 1998 | 2020 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 348 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2023 | 2987 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2019 | 23338 | 0.020 |
Why?
|
| Osteolysis | 1 | 2012 | 270 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2000 | 86 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3129 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1998 | 2187 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1997 | 1640 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 69 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 1996 | 956 | 0.020 |
Why?
|
| Peptides | 1 | 2002 | 4409 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 873 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2004 | 480 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 1801 | 0.020 |
Why?
|
| STAT2 Transcription Factor | 2 | 2000 | 27 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1993 | 1032 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2016 | 1538 | 0.020 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2000 | 66 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1889 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2016 | 13033 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 159 | 0.020 |
Why?
|
| Janus Kinase 1 | 2 | 2000 | 104 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Plasmids | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 1095 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 1519 | 0.020 |
Why?
|
| DNA, Viral | 3 | 2000 | 2225 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 2008 | 109 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2002 | 5021 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2012 | 729 | 0.020 |
Why?
|
| Biological Transport | 1 | 1993 | 2118 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 20129 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 970 | 0.020 |
Why?
|
| International Agencies | 1 | 2008 | 240 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 2 | 2000 | 320 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12026 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2000 | 1101 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 1012 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 6114 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2006 | 26 | 0.020 |
Why?
|
| Bone Transplantation | 2 | 2005 | 907 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2022 | 14557 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2007 | 201 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2616 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 399 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 2599 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 459 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5456 | 0.020 |
Why?
|
| Introns | 1 | 2008 | 991 | 0.020 |
Why?
|
| Janus Kinase 2 | 2 | 2000 | 528 | 0.020 |
Why?
|
| Lactones | 1 | 2008 | 329 | 0.020 |
Why?
|
| Ligands | 2 | 2002 | 3282 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 2 | 1997 | 433 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 326 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 1057 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2001 | 1460 | 0.020 |
Why?
|
| Family | 1 | 2016 | 3147 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2005 | 329 | 0.020 |
Why?
|
| Tea | 1 | 2006 | 275 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 14722 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 300 | 0.020 |
Why?
|
| Syndecans | 1 | 2004 | 79 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 840 | 0.020 |
Why?
|
| Monocytes | 1 | 1994 | 2596 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2006 | 298 | 0.010 |
Why?
|
| Heterozygote | 1 | 2011 | 2804 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2004 | 517 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2008 | 907 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2004 | 297 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 225 | 0.010 |
Why?
|
| Forecasting | 1 | 2012 | 2951 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 898 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 317 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2004 | 165 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 573 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2012 | 2072 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 279 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
| Pedigree | 1 | 2011 | 4644 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 381 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10388 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 943 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 128 | 0.010 |
Why?
|
| Exons | 1 | 2008 | 2437 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2010 | 3913 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8301 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 336 | 0.010 |
Why?
|
| Pyrroles | 1 | 2008 | 1146 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 411 | 0.010 |
Why?
|
| Cell Separation | 1 | 2007 | 1751 | 0.010 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2000 | 45 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 751 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 853 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 835 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2000 | 122 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2000 | 117 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2000 | 344 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 772 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 563 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1144 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2000 | 364 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2000 | 234 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 258 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 599 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2006 | 1530 | 0.010 |
Why?
|
| International Cooperation | 1 | 2006 | 1420 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 71 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 743 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 793 | 0.010 |
Why?
|
| Melphalan | 1 | 2000 | 431 | 0.010 |
Why?
|
| Hybridomas | 1 | 2000 | 452 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 258 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 595 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 822 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1284 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2000 | 698 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2000 | 337 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 1466 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2007 | 2504 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1997 | 46 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 2088 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 1607 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 1997 | 101 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1999 | 320 | 0.010 |
Why?
|
| TYK2 Kinase | 1 | 1997 | 38 | 0.010 |
Why?
|
| SOS1 Protein | 1 | 1997 | 41 | 0.010 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1997 | 34 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1998 | 253 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1997 | 103 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 852 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 755 | 0.010 |
Why?
|
| Aging | 1 | 1996 | 8664 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1998 | 829 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1997 | 126 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1999 | 645 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 648 | 0.010 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1997 | 139 | 0.010 |
Why?
|
| Flavonoids | 1 | 2000 | 443 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 2699 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 6234 | 0.010 |
Why?
|
| Child | 2 | 1996 | 77709 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2219 | 0.010 |
Why?
|
| Rats | 1 | 1993 | 24260 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1997 | 365 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2002 | 1338 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 7149 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 1206 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1483 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2203 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 1461 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 10180 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1613 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1997 | 380 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 726 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 1997 | 538 | 0.010 |
Why?
|
| DNA Replication | 1 | 2000 | 1399 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 1856 | 0.010 |
Why?
|
| Temperature | 1 | 2000 | 2206 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1997 | 581 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1998 | 1539 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 1997 | 912 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2003 | 1859 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 6473 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 1224 | 0.010 |
Why?
|
| Proteins | 2 | 1997 | 6103 | 0.010 |
Why?
|
| Antibodies | 1 | 2000 | 2460 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 2622 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 3508 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 7301 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 19905 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1998 | 3748 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15540 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1997 | 4851 | 0.000 |
Why?
|
| Repressor Proteins | 1 | 1997 | 3023 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7181 | 0.000 |
Why?
|